Lakefront Biotherapeutics NV (LKFT.AS) News
Follow Lakefront Biotherapeutics NV (LKFT.AS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Lakefront Announces Sale Of Preclinical Car — T Programs To Armed Cell Therapeutics
Oct 14 (Reuters) — Lakefront Biotherapeutics NV: Lakefront Announces Sale Of Preclinical Car-t Programs To Armed Cell Therapeutics Lakefront Biotherapeutics Nv: Armed Cell Therapeutics To Independently Advance Bought Cel
NEWS | Oct 14, 2026, 09:04 PM UTC
L
Lakefront completes sale of preclinical CAR — T programs to Armed Cell Therapeutics
Lakefront Biotherapeutics completed the sale of its preclinical cell therapy pipeline to Belgium-based Armed Cell Therapeutics on October 14, 2026. Terms include an upfront payment of €8 million, potential milestone paym
NEWS | Oct 14, 2026, 08:04 PM UTC